2013年 IAAO

国際フォーラム2013(IAAO2013)

Theme:Frontier in Oncology Therapy

Opening Remarks

00OpeningRemarks Osamu Nagayama

Chairman Chugai Academy for Advanced Oncology

1. Non-genetic dysregulation in tumor

▶ TGFβ Signaling in Cancer

01-1KoheiMiyazono
Speaker:
Kohei Miyazono, MD, PhD
The University of Tokyo, Japan
Chair:
Bruce A.Chabner, MD
Harvard Medical School, USA
01-2BruceA

▶ Targeting Cancer Metabolism

01-3ChiVanDang
Speaker:
Chi Van Dang, MD, PhD
The University of Pennsylvania, USA
Chair:
Kohei Miyazono, MD, PhD
The University of Tokyo, Japan
01-4KoheiMiyazono

2. Genetic dysregulation in tumor

▶ Targeting Activated HER2 in Solid Tumors

02-1MarkSliwkowski
Speaker:
Mark Sliwkowski, PhD
Genentech Inc., USA
Chair:
Masakazu Toi, MD, PhD
Kyoto University, Japan
02-2MasakazuToi

▶ The Power of One: Use of Whole Genome Outlier Analysis to Identify Occult Biomarkers of Drug Response

02-3DavidB
Speaker:
David B. Solit, MD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Hiroyuki Mano, MD, PhD
The University of Tokyo, Japan
02-4HiroyukiMano

▶ Role of Mutations in Epigenetic Regulators in Pathogenesis of Myeloid Malignancies

02-5RossL
Speaker:
Ross L. Levine, MD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Yuko Kitagawa, MD, PhD
Keio University, Japan
02-6YukoKitagawa

3. Tumor immunotolerance : basic and applications

▶ Immune Checkpoint Blockade in Cancer Therapy: New Insights & Opportunities

03-1JamesP
Speaker:
James P. Allison, PhD
The University of Texas, USA
Chair:
Makoto Ogawa, MD
Emeritus President, Aichi Cancer Center, Japan
03-2MakotoOgawa

▶ Immune Monitoring on Pre-surgical Clinical Trials with Anti-CTLA-4: Implicating the ICOS/ICOSL Pathway in Anti-tumor Immune Responses

03-3PadmaneeSharma
Speaker:
Padmanee Sharma, MD, PhD
The University of Texas, USA
Chair:
Kiyohiko Hatake, MD, PhD
Cancer Institute Hospital, JFCR, Japan
03-4KiyohikoHatake

4. Right drugs on right patients

▶ Approaches to Hypothesis Based Combination Therapy for Cancer

04-1NealRosen
Speaker:
Neal Rosen, MD, PhD
Memorial Sloan-Kettering Cancer Center,USA
Chair:
Mitsuaki Yoshida, PhD
Cancer Chemotherapy Center, JFCR, Japan
04-2MitsuakiYoshida

▶ Understanding and Targeting Mechanisms of Resistance to Next Generation AR and AR Signaling Inhibitors

04-3HowardI
Speaker:
Howard I. Scher, MD
Memorial Sloan-Kettering Cancer Center, USA
Chair:
Patrick G. Johnston, MD, PhD
The Queen´s University of Belfast, UK
04-4GJohnston

▶ Targeting Oncogenic Drivers in Lung Cancer

04-7PasiA
Speaker:
Pasi A. Jänne, MD, PhD
Harvard Medical School, USA
Chair:
Nagahiro Saijo, MD, PhD
Japanese Society of Medical Oncology, Japan
04-8NagahiroSaijo

▶ Targeting Clinically Relevant Molecular Subtypes in Colorectal Cancer

04-5PatrickG
Speaker:
Patrick G.Johnston, MD, PhD
The Queen´s University of Belfast, UK
Chair:
Chikashi Ishioka, MD
Tohoku University, Japan
04-6ChikashiIshioka

5. Accessibility to new drugs

▶ Changing the Regulatory Pathway for Targeted Drugs

05-1BruceA
Speaker:
Bruce A. Chabner, MD
Harvard Medical School, USA
Chair:
Isao Kamae, MD, ScD
The University of Tokyo, Japan
05-2IsaoKamae

▶ Health Technology Assessment: Changing Landscape in Asia and Japan

05-3IsaoKamae
Speaker:
Isao Kamae, MD, ScD
The University of Tokyo, Japan
Chair:
Yasuhiro Fujiwara, MD, PhD
National Cancer Center, Japan
05-4YasuhiroFujiwara

Discussion

05-5BruceA
Chair:
Bruce A. Chabner, MD
Harvard Medical School, USA
一般社団法人 中外Oncology学術振興会議